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● Patient demographics and tumor characteristics are summarized in Table 1.
o It is interesting to note an apparent imbalance in certain clinical attributes between the
two CYAD-01 administration schedules arms. Patients (pts) enrolled onto the dose dense
schedule appear to have a higher average bone marrow (BM) blast count and lower average
platelet and neutrophil counts suggestive of greater cancer disease burden and
pancytopenic status at baseline as compared to pts enrolled in the biweekly schedule.
● The patient incidence of treatment-related adverse events (AEs) (CARTOX grading for
cytokine release syndrome (CRS), NCI-CTCAE, Version 5.0 for other AEs) is summarized in
Table 2.
o An encouraging safety profile was observed with 11 pts out of 25 with Grade (G) 3/4
treatment-related AEs. The dose dense schedule did not modify the overall safety profile
so far.
o CRS occurred in 13 pts with four G3 and two G4 events, which resolved with tocilizumab
treatment. No treatment-related neurotoxicity AEs were reported.
o There were two DLTs at 3x109 (DL-3) cells per infusion, one CRS G4 DLT in the biweekly
schedule (24 infusions) and one CRS G3 DLT with the dose dense schedule (15 infusions -
cohort ongoing).
● Encouraging anti-leukemic activity was observed in 8 pts with BM blasts decrease including
5 objective responses and 1 SD for ≥ 3 months according to the ELN2017 recommendations
(AML) or Revised IPSS (MDS) (Figure 2).
o One of these pts presenting a SD for < 3months died of infectious disease at Day 50 with a
68% BM blast decrease after the 1st cycle of 3 CYAD-01 infusions (Day 32).
o Most responses, with the exception of the two pts bridging to an allograft
procedure, were of short durability (Figure 1).
o Albeit with insufficient patient numbers to enable a statistical conclusion, the anti-
leukemic activity appeared predominantly observed in pts in the non-Adverse ELN2017
(AML)/non-Very High R-IPSS (MDS) risk stratification categories.
● There was some evidence of dose-dependence engraftment of CYAD-01 cells (Figure 3).
However, there was no strong evidence of correlation of dose with clinical activity in the study
to date.
MAIN RESULTSTABLES & FIGURES
CONCLUSIONS AND PERSPECTIVES
● The current results support a good safety profile of a multiple dose schedule with CYAD-01
without prior preconditioning chemotherapy in r/r AML/MDS patients.
● The anti-leukemic activity rate, although mostly of short durability, is promising in such
refractory patient population. Even if the overall sample size of this Phase I study is small, this
clinical activity does not seem to be correlated to the dose-levels and is predominantly
observed in the non-Adverse ELN2017/non-Very High R-IPSS risk stratification categories.
● The clinical activity data obtained recently with the dose dense schedule cohorts did not
demonstrate an improvement of the clinical outcome. However, it is important to outline that
these last enrolled pts presented with greater BM blasts infiltration and apparent more
profound pancytopenic status at baseline than the first enrolled patients who received the
biweekly schedule. Whether this blunted CYAD-01 activity remains open to question.
● Given the tolerability and short-term clinical activity of CYAD-01, efforts have been made to
optimize the manufacturing process (“OptimAb”) under the same IND, to enrich for early
memory phenotype CAR T-cells that showed enhanced anti-tumor activity in preclinical
models (poster 3844).
● Further recruitment into the THINK trial will use the OptimAb manufacturing process.
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Data cut-off: 19 November 2019
Biweekly schedule Dose dense schedule
DL-1 DL-2 DL-3 Total DL-2 DL-3 Total
3x108 1x109 3x109 1x109 3x109
N=6 N=3 N=7 N=16 N=4 N=5 N=9
Age (years): Mean (Range) 64.8 (52-79) 74.0 (60-83) 60.1 (29-80) 64.5 (29-83) 61.3 (29-80) 69.8 (48-85) 66.0 (29-85)
Gender: Male/Female 5/1 2/1 6/1 13/3 1/3 3/2 4/5
ECOG performance score at screening  (Grade 
0/1/2)
2/4/0 2/1/0 2/5/0 6/10/0 2/2/0 0/4/1 2/6/1
LVEF (%): Mean (Range) 58.8 (48-66) 64.7 (55-79) 61.3 (55-67) 61.0 (48-79) 58.8 (52-65) 56 (50-60) 57.2 (50-65)
Tumor type           
3 3 6 12 3 4 7r/r Acute Myeloid Leukemia 
De novo 2 2 5 9 3 2 5
AML MRC/secondary AML 1 1 1 3 0 2 2
r/r Myelodysplastic Syndrome 0 0 1 1 1 1 2
r/r Multiple Myeloma 3 0 0 3 0 0 0
ELN 2017/R-IPSS Risk Stratification for 
AML/MDS
Favorable (AML)/Intermediate (MDS) 1/0 1/0 0/1 2/1 0/0 0/0 0/0
Intermediate (AML)/High-Risk (MDS) 2/0 0/0 1/0 3/0 2/1 0/0 2/1
Adverse (AML)/Very High-Risk (MDS) 0/0 2/0 5/0 7/0 1/0 4/1 5/1
Bone marrow blasts (%)  mean (range) 9.5 (0.0-21.0) 27.3 (9.8-48.2) 12.2 (4.0-20.0) 14.0 (0.0-48.2) 41.5 (15.0-82.0) 37.5 (9.0-58.0) 39.3 (9.0-82.0)
Platelets (103/μL)   mean (range) 127.7 (22.0-261.0) 101.3 (63.0-144.0) 53.6 (6.0-157.0) 90.3 (6.0-261) 72.0 (39.0-159.0) 45.4 (24.0-74.0) 57.2 (24.0-159.0)
ANC (103/μL) mean (range) 2.13 (0.0-8.1) 1.28 (0.14-3.46) 1.27 (0.09-2.59) 1.6 (0.0-8.1) 0.66 (0.12-2.08) 0.58 (0.18-0.99) 0.6 (0.1-2.1)
Data cut-off: 19 November 2019
Biweekly schedule Dose dense schedule
DL-1 (3x108)
6 patients (15 inf.)
DL-2 (1x109)
3 patients (12 inf.)
DL-3 (3x109)
7 patients (24 inf.)
Total
16 patients (51 inf.)
DL-2 (1x109 ) 
4 patients  (15 inf.)
DL-3 (3x109 )
5 patients  (15 inf.)
Total
9 patients (30 inf.)
All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4
Patients with at least 1 related AE (N.%) 6 (100%) - 1 (17%) 3 (100%) 2 (67%) - 6 (86%) 1 (14%) 3 (43%) 15  (94%) 3 (19%) 4 (25%) 4 (100%) - 1 (25%) 3 (60%) 2 (40%) 1 (20%) 7 (78%) 2 (22%) 2 (22%)
Cytokine release syndrome (CRS) 1 (17%) - - 2 (67%) 2 (67%) - 4 (57%) - 1 (14%) (1) 7 (44%) 2 (13%) 1 (6%) 3 (75%) - - 3 (60%) 2 (40%) (1) 1 (20%) 6 (67%) 2 (22%) (1) 1 (11%)
Hypoxia 1 (17%) - 1 (17%) 3 (100%) - - - - - 4 (25%) - 1 (6%) 1 (25%) - - - - - 1 (11%) - -
Pneumonitis 1 (17%) - 1 (17%) - - - - - - 1 (6%) - 1 (6%) - - - - - - - - -
Fatigue 2 (33%) - - - - - 1 (14%) 1 (14%) - 3 (19%) 1 (6%) - - - - - - - - - -
Headache - - - - - - 1 (14%) 1 (14%) - 1 (6%) 1 (6%) - - - - - - - - - -
Infusion related reaction 1 (17%) - - - - - - - - 1 (6%) - - 1 (25%) - 1 (25%) - - - 1 (11%) - 1 (11%)
Pain in extremity - - - - - - - - - - - - - - - 1 (20%) 1 (20%) - 1 (11%) 1 (11%) -
Lymphopenia 1 (17%) - 1 (17%) 1 (33%) - - 1 (14%) - 1 (14%) 3 (19%) - 2 (13%) - - - - - - - - -
Thrombocytopenia - - - 1 (33%) 1 (33%) - 1 (14%) - 1 (14%) 2 (13%) 1 (6%) 1 (6%) - - - - - - - - -
(1) Dose-limiting toxicity (DLT)
T a b l e  2 :  I n c i d e n c e  o f  t r e a t m e n t - r e l a t e d  a d v e r s e  e v e n t s  ( A E s )  r e p o r t e d  a t  l e a s t  o n c e  a s  ≥ G r a d e  3
T a b l e  1 :  P a t i e n t  c h a r a c t e r i s t i c s
F i g u r e  1 :  T i m e  t o  r e s p o n s e  a n d  d u r a t i o n  o f  t r e a t m e n t  i n  A M L / M D S  p a t i e n t s
AlloHSCT: allogeneic human stem cell transplant; CR: complete
remission; CRi: CR with incomplete hematologic recovery;
CRh: CR with partial hematologic recovery; CRMRD-: CR without minimal
residual disease; DLT: dose-limiting toxicity; ELN: European
LeukemiaNet; LTFU: lost to follow-up; mCR: marrow CR; m: month; ne:
non-evaluable; PD: progressive disease; PR: partial remission; R-IPSS:




















● The rapid approval of two anti-CD19 chimeric antigen receptor (CAR)
T-cell therapies and advanced development of anti-BCMA CAR T-cell
therapies demonstrate the potential of the approach in B-cell
malignancies. However, targets with a similar profile for CAR T-cell
therapy in other diseases including acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) are lacking.
● CYAD-01 is an autologous CAR T-cell therapy engineered with a multi-
complex, second-generation NKG2D CAR comprising the full-length
human natural killer group 2D (NKG2D) receptor fused to the
intracellular domain of CD3ζ.
● The NKG2D receptor targets 8 ligands (MHC class I chain related
proteins A [MICA] and B [MICB] and unique long 16 binding proteins
[ULBP] 1–6 ligands) found at high frequency across a range of
malignancies. Interestingly, non-malignant cells within the tumor
microenvironment (myeloid-derived suppressor cells, regulatory T-
cells and neo-endothelial cells) also express NKG2D ligands which led in
preclinical models to the induction by CYAD-01 of a broader anti-tumor
response beyond direct cancer cell killing.
● CYAD-01 is being evaluated in relapsed/refractory (r/r) AML/MDS
patients, with the objective to define whether the optimal CYAD-01
treatment is with prior preconditioning chemotherapy (DEPLETHINK
study, poster 3844) or without any pretreatment (THINK study, here
discussed).
● The open-label Phase I THINK study (NCT03018405) evaluates
multiple administrations of CYAD-01 in r/r AML, MDS and multiple
myeloma (MM) patients without any prior non-myeloablative
preconditioning or bridging therapy.
● The study design:
o Dose escalation segment with a Fibonacci 3+3 design evaluating (i)
three dose levels (DL) of CYAD-01: 3x108 (DL-1), 1x109 (DL-2), and
3x109 (DL-3) cells per infusion, and (ii) two administration
schedules for the 1st cycle of 3 CYAD-01 infusions: every two weeks
(biweekly schedule) or weekly (dose dense schedule). The dose
dense schedule evaluates only the 1x109 (DL-2) and 3x109 (DL-3)
cells per infusion.
o Expansion segment with the selected dose and schedule.
● Potential new cycle of treatment (3 infusions every two weeks) in the
absence of progression at the end of the first cycle (1x109 or 3x109
cells/infusion).
● Primary endpoint of the dose escalation segment is the occurrence of
dose-limiting toxicity (DLT) during the CYAD-01 treatment phase.
Patients who have not completed their first cycle of CYAD-01
administrations for other reasons than DLT should be replaced. Key
secondary endpoints include additional safety parameters, objective




● 25 patients have been enrolled so far in the dose escalation segment
(ongoing).
● Safety analysis is presented for the total treated patient population
who received at least one CYAD-01 infusion, including three MM
patients enrolled at the DL-1 biweekly schedule. Clinical activity and
cells engraftment are presented for the 22 r/r AML/MDS patients.
(1) Evaluable patients for whom the first planned bone marrow evaluation or an early documented bone marrow in case of
progressive disease was performed. Seven patients, including two patients with dose-limiting toxicity at the first
CYAD-01 infusion, did not have post-baseline bone marrow data available and therefore are not reported on the graph
ELN 2017 (AML) / R-IPSS (MDS)
Favorable / Intermediate
Intermediate / High risk
Adverse / Very High risk AlloHSCT3x10
9 cells/infusion
3x108 cells/infusion Disease Progression
1x109 cells/infusion Death
CYAD-01 Salvage chemotherapy 
F i g u r e  2 :  B e s t  c h a n g e  i n  B M  b l a s t  c o u n t  f r o m  b a s e l i n e  i n  A M L / M D S  p a t i e n t s  ( % ) ( 1 )
24% 9% 48% 15% 82% 15% 10% 24% 6% 51% 7% 9%
BM blasts at 
baseline 15%
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F i g u r e  3 :  C Y A D - 0 1  k i n e t i c s  i n  t h e  p e r i p h e r a l  b l o o d
Highest peak AUC0‐31days data
Red dots indicate the patients in CR/PR. AUC: area under the curve
AUC was calculated using the linear trapezoidal rule. The number of copies of the transgene per μg of genomic DNA isolated from PBMCs 
and measured by digital droplet PCR at prespecified timepoints was used. AUC is reported from the time of first dosing to 31 days.
